Our Vision & Strategy
BioNTech’s vision is to become the leading global biotechnology company providing individualized treatments for cancer patients and improved therapeutics to treat infectious and rare diseases.
We aim to build and leverage the building blocks of immunotherapy:
- Our technology platforms and clinical pipeline are based on 20 years of research and development expertise.
- Fully integrated biotech company spanning research through clinical development and manufacturing to sales and marketing.
- Unique go-to-market strategy, entering differentiated licensing, co-development and co-commercialization agreements, making BioNTech an equal development partner.
BioNTech’s product-to-market offering of truly individualized cancer treatments will be realized through its differentiated technology platforms.
Lead program: iNeST (Individualized NeoAntigen Specific Immunotherapy) targets cancer mutations or “neoantigens” and could therefore be universally applicable across cancer types.